Health care operations do not require affected individual authorizations and so are eligible for remuneration as associated costs. AMIA supports inclusion of genuine treatment communications, such as educational support materials distributed by Covered Entities, in the definition of qualified health care procedures. AMIA supports the chance for sufferers to 'opt out' of potential fundraising solicitations, but will not see a advantage to offering 'opt out' statements prior to 1st solicitations. Prohibition of Sale of PHI Position: AMIA opposes a switch in the current description for Limited Data Sets from not completely identifiable protected health details to completely identifiable PHI, which would prohibit the sale of LDSs, and offer little incentive for Covered Entities to generate, maintain, use, and provide large electronic data sets.Trial Design The Phase 2 trial can be an open-label, multicenter trial to evaluate the efficacy and basic safety of ponatinib in individuals with metastatic and/or unresectable GIST after prior failing of at least one TKI. Patients whose tumors possess an activating mutation in exon 11 of cellular Package, the principal driver for individuals with Package and GIST mutations, will be enrolled in Cohort A. Patients whose tumors have additional activating mutations will end up being enrolled into Cohort B.